美国食品药品管理局(FDA)近日批准阿地溴铵(Tudorza Pressair),用于治疗与慢性阻塞性肺病相关的支气管痉挛(肺气道变窄),包括慢性支气管炎和肺气肿的长期维持治疗。慢阻肺是一种导致呼吸困难的严重的肺部疾病。美国心脏、肺和血液研究所指出,吸烟是导致慢性阻塞性肺病的主要原 The U.S. Food and Drug Administration (FDA) recently approved Tudorza Pressair for the treatment of bronchospasm associated with chronic obstructive pulmonary disease (pulmonary constriction), including long-term maintenance of chronic bronchitis and emphysema treatment. COPD is a serious lung disease that causes breathing difficulties. American Heart, Lung and Blood Institute pointed out that smoking is the leading cause of chronic obstructive pulmonary disease